CHICAGO and FORT WORTH, Texas, May 06, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on ...

(RTTNews) - Actuate Therapeutics, Inc. (ACTU) Tuesday reported positive results from the Phase 2 study of elraglusib in combination with chemotherapy drugs ...

Actuate Therapeutics CHICAGO and FORT WORTH, Texas, April 30, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage ...

Actuate is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers. Actuate’s lead investigational drug ...

The webcast of the presentation will be accessible in the Investor section of the Actuate website. The Actuate management team will participate in one-on-one investor meetings during this event.